Adenocarcinoma of colon

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
7 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
V Various (ATC V) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Antimetabolite 2 substances
Monoclonal antibody (immune) 1 substance
Supportive / rescue 1 substance
Platinum compound 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Unknown / small molecule 1 substance
Phase III: 2 Phase II: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Glaxosmithkline Research & Development Limited Commercial
    CAPECITABINE; DOSTARLIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN
    2023-503265-27-00 14 countries 2023 n=543
    Ended
  • Centre Hospitalier Universitaire De Dijon Academic
    IMP not specified
    2023-505214-23-00 1 country 2024 n=150
    Recruiting

Phase II

2 trials
  • AIO-Studien gGmbH Academic
    ATEZOLIZUMAB; MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
    2024-515224-37-00 1 country 2023 n=80
    Ended
  • Gruppo Oncologico Del Nord Ovest Academic
    IMP not specified
    2023-505356-22-00 1 country 2024 n=46
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 0
AIO-Studien gGmbH Academic 1 Phase II 0
Gruppo Oncologico Del Nord Ovest Academic 1 Phase II 0
Centre Hospitalier Universitaire De Dijon Academic 1 Phase III 1
New trials by year
2023
2
2024
2
← All indication landscapes